Document Detail


Creatine monohydrate attenuates body fat accumulation in children with acute lymphoblastic leukemia during maintenance chemotherapy.
MedLine Citation:
PMID:  18421708     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Corticosteroids are an important component of the treatment of acute lymphoblastic leukemia (ALL), with known significantly negative effects on bone and muscle. Creatine monohydrate (CrM) supplementation may be an adjunctive therapeutic strategy to attenuate some of these adverse effects. PROCEDURE: Nine children with ALL in the maintenance phase of treatment on the Dana-Farber Cancer Institute (DFCI) protocol 2000-2001 were treated with CrM (0.1 g/kg/day) for two sequential periods of 16 weeks (16 weeks treat > 6 weeks wash-out > 16 weeks treat). A cohort of children (N = 50) who were receiving the same chemotherapy at the same time served as natural history controls. Measurements included height, weight, body mass index (BMI), and lumbar spine bone mineral density (LS-BMD), whole body bone mineral content (WB-BMC), fat-free mass (FFM), and percent body fat (%BF) using dual-energy X-ray absorptiometry. RESULTS: Despite the long course of corticosteroid treatment for ALL, children showed significant increases in height, LS-BMD, WB-BMC and FFM over approximately 38 weeks (P < 0.05) during the study. There was an increase in BMI over time, but children taking CrM had a reduction, while the natural history group showed an increase in % BF (P < 0.05 for interaction). CONCLUSIONS: Children with ALL treated with corticosteroids as part of a maintenance protocol of chemotherapy showed an increase in % BF that was attenuated by CrM supplementation.
Authors:
Jacqueline M Bourgeois; Kim Nagel; Erin Pearce; Marilyn Wright; Ronald D Barr; Mark A Tarnopolsky
Related Documents :
23927958 - Increase in pediatric magnet-related foreign bodies requiring emergency care.
11822578 - Leptin, insulin-like growth factor (igf)-i and igf binding protein-3 levels in children...
19717008 - Recombinant human insulin-like growth factor-1 treatment: ready for primetime.
12035938 - Short children with familial short stature show enhancement of somatotroph secretion bu...
12030998 - Functional status of school-aged children with down syndrome.
8313308 - Have the invisible children become visible?
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Pediatric blood & cancer     Volume:  51     ISSN:  1545-5017     ISO Abbreviation:  Pediatr Blood Cancer     Publication Date:  2008 Aug 
Date Detail:
Created Date:  2008-06-12     Completed Date:  2008-06-24     Revised Date:  2009-01-12    
Medline Journal Info:
Nlm Unique ID:  101186624     Medline TA:  Pediatr Blood Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  183-7     Citation Subset:  IM    
Affiliation:
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada. bourjac@hhsc.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adipose Tissue / metabolism*
Adolescent
Adrenal Cortex Hormones / adverse effects
Body Composition / drug effects
Child
Child, Preschool
Creatine / administration & dosage*
Dietary Supplements
Female
Humans
Male
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*,  metabolism
Retrospective Studies
Chemical
Reg. No./Substance:
0/Adrenal Cortex Hormones; 57-00-1/Creatine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The motor activity of mammalian axonemal dynein studied in situ on doublet microtubules.
Next Document:  C-erbB-2 expression and prognostic significance in osteosarcoma.